| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| resistance to trastuzumab in breast cancer | 0.74 | 0.7 | 1388 | 97 | 42 |
| resistance | 0.85 | 0.2 | 7413 | 24 | 10 |
| to | 1.17 | 0.5 | 177 | 82 | 2 |
| trastuzumab | 0.95 | 0.1 | 7548 | 64 | 11 |
| in | 0.9 | 0.9 | 8752 | 89 | 2 |
| breast | 0.04 | 0.9 | 4325 | 9 | 6 |
| cancer | 0.22 | 1 | 771 | 14 | 6 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| resistance to trastuzumab in breast cancer | 1.88 | 0.4 | 4354 | 33 |
| trastuzumab in breast cancer | 0.39 | 0.2 | 766 | 47 |
| trastuzumab in the treatment of breast cancer | 0.25 | 0.5 | 4180 | 3 |
| trastuzumab metastatic breast cancer | 0.57 | 1 | 7454 | 17 |
| adjuvant trastuzumab breast cancer | 1.21 | 0.5 | 1666 | 50 |
| trastuzumab side effects breast cancer | 1.73 | 0.2 | 1742 | 92 |
| trastuzumab her2-positive breast cancer | 1.99 | 0.6 | 3069 | 51 |
| drug resistance in breast cancer | 0.09 | 0.8 | 477 | 80 |
| pertuzumab and trastuzumab resistance | 1.64 | 0.7 | 5802 | 8 |
| trastuzumab-resistant | 1.24 | 0.6 | 6137 | 11 |
| trastuzumab deruxtecan breast cancer | 1.56 | 1 | 5301 | 18 |
| metastatic breast cancer therapy resistance | 1.39 | 0.2 | 3975 | 28 |
| her2 mutation trastuzumab resistance | 0.23 | 0.9 | 8509 | 35 |
| cdk12 and trastuzumab resistance | 1.89 | 0.6 | 7101 | 82 |
| trastuzumab and gastric cancer | 1.9 | 0.1 | 667 | 41 |
| trastuzumab deruxtecan her2 low breast cancer | 0.56 | 0.3 | 7016 | 69 |
| trastuzumab chemotherapy or immunotherapy | 1.07 | 0.1 | 8483 | 34 |
| molecular weight of trastuzumab | 0.6 | 0.7 | 5659 | 24 |
| trastuzumab cardiac toxicity reversible | 0.04 | 0.2 | 8776 | 60 |
